secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-07-20T11:35:14+00:00
Accession:  0001193125-26-308343
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Dyne's BLA for DYNE-251 in DMD exon 51 skipping; Priority Review granted
--------------------------------------------------------------------------------

- FDA accepted BLA for z-rostudirsen (DYNE-251) to treat Duchenne muscular dystrophy amenable to exon 51 skipping.
- Priority Review assigned; PDUFA target action date is January 21, 2027.
- Company expects potential U.S. launch in Q1 2027 if approved on anticipated timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/0001193125-26-308343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526308343/dyn-20260720.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-308343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer